Earnings Release • Feb 19, 2021
Earnings Release
Open in ViewerOpens in native device viewer
publication: 19.02.2021 13:50 source: http://adhoc.pressetext.com/news/1613739000471 keywords: Marinomed Biotech AG / update / research / Carragelose
Public disclosure of inside information according to article 17 MAR
Korneuburg (pta026/19.02.2021/13:50) - February 19, 2021
Marinomed Biotech AG (VSE:MARI) announces that a nasal spray with iota-carrageenan, which is identical to Marinomed's Carragelose®, showed significant efficacy in the prevention of COVID-19 in hospital staff who manage patients with this disease. These were the results of an independent and investigator-initiated study (IIT; CARR-COV-02, NCT04521322) conducted by an Argentinian research group.
In the multicenter, randomized, double-blind, controlled CARR-COV-02 study, 394 healthcare staff were randomly assigned to receive iota-carrageenan nasal spray (N = 199) or placebo (N = 195) four times per day. Both groups had similar gender and age distributions. The percentage of participants that developed COVID-19 was significantly lower in the group that received the iotacarrageenan spray compared to placebo (1.0% vs 5.1%, respectively; relative risk reduction for disease of 80.4 %; 95 % CI = 25-95 % - there is a 95 % chance that the risk reduction is in this range). The difference between the groups were statistically significant (Chi square test p = 0.01). Iota-carrageenan nasal spray was safe and well tolerated, and minor side effects, such as postnasal drip, were observed with a similar frequency in both groups (2.0 %).
The investigator-initiated CARR-COV-02 study (NCT04521322) was conducted by an Argentinian research group represented by Dr. Juan M. Figueroa, Institute of Science and Technology Cesar Milstein-Hospital de Clínicas-UBA; Dr. Mónica Lombardo, Nobeltri SRL and Hospital Universitario CEMIC; Dr. Ariel Dogliotti, Rosario Cardiovascular Institute; Dr. Luis P. Flynn, Sanatorium of Children of Rosario; Dr. Osvaldo Uchitel, Institute of Physiology, Molecular Biology and Neurosciences UBA-CONICET.
The data have been published on the website of the Instituto de Ciencia y Tecnología César Milstein: https://milstein.conicet.gov.ar/la-eficacia-del-spray-nasal-con-carragenina-para-la-prevencion-del-covid-19-ha-dado-resultadospositivos/
For further inquiries contact: Dr. Eva Prieschl-Grassauer Chief Scientific Officer, Marinomed Hovengasse 25, 2100 Korneuburg, Austria T +43 2262 90300 E-mail: [email protected] https://www.marinomed.com International Media Contact MC Services AG Dr. Brigitte Keller, Julia Hofmann T +49 89 210228 0 UK: Shaun Brown M: +44 7867 515 918 E-mail: [email protected]
Media Contact Austria Metrum Communications GmbH Roland Mayrl T +43 1 5046987-331 E-Mail: [email protected]
This adhoc announcement contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this adhoc announcement whether as a result of new information, future developments or otherwise.
| emitter: | Marinomed Biotech AG Hovengasse 25 2100 Korneuburg Austria |
|---|---|
| contact person: | Elisabeth Schön |
| phone: | +43226290300 |
| e-mail: | [email protected] |
| website: | www.marinomed.com |
| ISIN(s): | ATMARINOMED6 (share) |
| stock exchanges: | official trade in Vienna |
News transmitted by pressetext.adhoc. The emitter is responsible for the content.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.